Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q2 FY25 results · Jul–Sep 2024
Torrent Pharmaceuticals reported revenue from operations of ₹2,889.00 crore (up 8.6% from Q2 FY24) and net profit of ₹453.00 crore (up 17.4% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,889.00 | 2,660.00 | +8.6% | 2,859.00 | +1.0% |
| Other income | (16.00) | 26.00 | Turned loss | 24.00 | Turned loss |
| Total income | 2,873.00 | 2,686.00 | +7.0% | 2,883.00 | −0.3% |
| Profit before tax | 661.00 | 559.00 | +18.2% | 656.00 | +0.8% |
| Net profit for the period | 453.00 | 386.00 | +17.4% | 457.00 | −0.9% |
| EPS, basic (₹) | 13.37 | 11.39 | +17.4% | 13.51 | −1.0% |
| Net margin (%) | 15.7 | 14.5 | 16.0 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,434.00 | 2,146.00 | +13.4% | 2,438.00 | −0.2% |
| Other income | (7.00) | 15.00 | Turned loss | 21.00 | Turned loss |
| Total income | 2,427.00 | 2,161.00 | +12.3% | 2,459.00 | −1.3% |
| Profit before tax | 670.00 | 482.00 | +39.0% | 667.00 | +0.4% |
| Net profit for the period | 460.00 | 327.00 | +40.7% | 469.00 | −1.9% |
| EPS, basic (₹) | 13.60 | 9.65 | +40.9% | 13.86 | −1.9% |
| Net margin (%) | 18.9 | 15.2 | 19.2 |
Consolidated
- Filed with BSE
- 28 Oct 2024, 12:54 IST
- Board meeting
- 25 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Oct 2024, 12:54 IST
- Board meeting
- 25 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Audited
- Source
- XBRL filing on BSE